Anthony leverages 12 years of building and managing a biotechnology company together with more than 18 years as a management consultant to the pharma and biotechnology industries.
Simon has more than two decades of experience managing and advising on strategic and product development issues.
Mike has over 35 years of experience leading a variety of functional and corporate planning assignments with Bio-/Pharmaceutical, Medical Product and Diagnostic companies.
Brian has 15 years of consulting and 10 years of industry experience leading a variety of functional, corporate planning and business development assignments in the Bio-Pharmaceutical, Medical Product and Diagnostic industries.
Peter is an experienced physician executive with over 30 years of experience in drug development, life sciences, and health care. As an industry advisor, he supports clients with a range of development challenges, with a particular focus on liver fibrosis, NASH, and GI pharma consulting.
Bill is a clinical drug developer and medical oncologist with more than 20 years’ experience in the biopharma industry.
Alastair brings 25 years of strategic planning and product commercialization experience across multiple disease areas in big pharma and start up environments. His consulting practice areas of focus are product strategy, launch planning, asset valuation, business development and portfolio review.
Stuart has significant experience of the life science and medical device industries, with 25 years of global work experience in the USA, Europe, Japan, China and Australasia.
Christine is a clinical drug developer with more than 25 years of experience in large pharma companies.
Saadia has experience in technology assessment of a wide range of life science technologies, market opportunity assessment, business-plan development, competitor landscape analysis, due diligence and asset valuations.
Chris is a Senior Consultant supporting a range of partnering and business development assignments.
Jess is a life science consultant with industry experience working across the drug development pipeline in academic, contract research, biotech, big pharma and regulatory agency roles.
Rob co-founded Alacrita in 2009 and opened Alacrita’s US office in Cambridge, Massachusetts in 2012. He provides business development, valuation and licensing support to biotech and pharma companies.
Anna has launched 13 products in oncology and rare diseases. She had direct P&L responsibility for global, European and individual country businesses. She built a successful European biotech business for a US-based company from scratch. Anna is responsible for Alacrita AG in Zug, Switzerland.